The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study
Abstract
Objectives: Chronic myeloproliferative diseases (CMPD) are neoplastic disorders leading to hypercoagulability and thrombosis. The critical hemostatic abnormalities include alterations in the blood viscosity and a history of recent thrombus. The aim of this study is to assess the interrelationships among the atherogenic index of plasma (AIP) and thromboembolism of CMPD with JAK2 V617F mutation.
Methods: Ninety-two patients diagnosed as CMPD with JAK2 V617F mutation and 73 controls were included into the study. The patients were evaluated for the presence of any venous or arterial thromboembolic events. AIP was calculated by using the formula log (Tg/HDL) from serum triglyceride and high-density lipoprotein values.
Results: The study group consisted of 30 patients (33%) with myelofibrosis (MF), 42 patients (46%) with polycythemia vera (PV) and 20 patients (21%) with essential thrombocythemia (ET). Two study groups were similar in terms of sex, age and other comorbidities (p > 0.05). CMPD group had higher levels of right blood cell count (RBC), red blood cell distribution width (RDW), platelets (PLT), hemotocrit (Hct) and AIP. Univariate and multivariate logistic regression analysis revealed that platelet count, RBC and AIP were independent predictors for thrombosis in both groups. The comparison of ROC curve analysis disclosed that AIP was superior to platelet count and RBC in predicting thrombosis.
Conclusion: AIP can be used to determinate higher risk of thromboembolism in patients with CMPD. As a reliable and ‘easy-to-assess’ diagnostic tool, AIP could be useful for the determination of thrombotic events in CMPD clinicobiological disease course.
Keywords
atherogenic index, myeloproliferative, Janus kinase, thromboembolism
References
- Bittencourt RI, Vassallo J, Chauffaille Mde L, Xavier SG, Pagnano KB, Nascimento AC, et al. Philadelphia-negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter. 2012;34(2):140-9.
- Uysal A, ALTINER Ş, Çelik S, Uysal S, Çebi AH. Genetic analysis of BCR-ABL negative chronic myeloproliferative diseases at initial diagnosis and their clinical effects. Cukurova Medical Journal. 2020;45(3):933-9.
- Azevedo AP, Silva SN, Reichert A, Lima F, Júnior E, Rueff J. Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. Biomed Rep. 2017;7(4):370-6.
- Kahraman CY, Sincan G, Tatar A. Evaluation of the Relationship between Janus Kinase 2 Mutational Burden and Clinical Findings in Adult Myeloproliferative Neoplasm Patients. Medical Bulletin of Haseki/Haseki Tip Bulteni. 2022;60(1).
- de Lacerda JF, Oliveira SN, Ferro JM. Chronic myeloproliferative diseases. Handb Clin Neurol. 2014;120:1073-81.
- Soyer N, Haznedaroğlu İ C, Cömert M, Çekdemir D, Yılmaz M, Ünal A, et al. Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turk J Haematol. 2017;34(1):27-33.
- Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176-84.
- Byrnes JR, Wolberg AS. Red blood cells in thrombosis. Blood. 2017;130(16):1795-9.
- Kuznetsova PI, Raskurazhev AA, Shabalina AA, Melikhyan AL, Subortseva IN, Tanashyan MM. Red Blood Cell Morphodynamics in Patients with Polycythemia Vera and Stroke. Int J Mol Sci. 2022;23(4).
- Geringer J, Fenderson J, Osswald M. Essential Thrombocythemia Complicated by Occlusive Thrombosis of the Abdominal Aorta. Case Rep Hematol. 2019;2019:9454501.